CheckMate 67T: Logistical Benefits, Considerations of Subcutaneous Nivolumab for RCC

Laurence Albiges, MD, PhD, of Gustave Roussy, expands on the findings from CheckMate 67T, which examines subcutaneous (subQ) administration of nivolumab for renal cell carcinoma. Dr. Albiges highlights the logistical advantages of subQ nivolumab, including reduced chair time and improved patient convenience, while addressing the challenges of integrating this modality into real-world practice. The discussion emphasizes the importance of patient education about the demonstrated non-inferiority of this approach, the need to address reimbursement logistics at national levels, and the critical role of clinical organization in implementation.